TEE
IOVA icon

Tibra Equities Europe’s Iovance Biotherapeutics IOVA Stock Holding History

Tibra Equities Europe’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19,100
Closed -$348K – 245
2019
Q3 		$348K Buy
+19,100
New +$422K 0.04% 174

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Tibra Equities Europe's IOVA Position: Q4 2019 in Review

Tibra Equities Europe sold out of Iovance Biotherapeutics (IOVA) in Q4 2019, closing a stake of 19,100 shares — an estimated $348K sold.

Tibra Equities Europe first reported a position in IOVA in Q3 2019 and held it in 1 quarter. The position peaked at $348K in Q3 2019. 200 funds tracked by Wall St. Rank hold IOVA as of Q4 2019.

  • Tibra Equities Europe reported no remaining Iovance Biotherapeutics position as of Q4 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 19,100 Iovance Biotherapeutics shares in Q4 2019, an estimated $348K.
  • Tibra Equities Europe first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Iovance Biotherapeutics position peaked at $348K in Q3 2019.
  • 200 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2019.

Based on Tibra Equities Europe's 13F filing for Q4 2019, filed 14 Feb 2020.